Here’s whether Cogent Biosciences, Inc. Common Stock (COGT) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); RSI 55 — healthy momentum range; strong 1-year return of +772.4%. Concerns: 50-day MA is falling (-0.66% over 10 days). Currently 14.8% off its 52-week high. Score: +4/7.
COGT is in a confirmed uptrend, trading above both its 50-day ($36.68) and 200-day ($26.19) moving averages. An RSI of 54.9 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +772.4% compares to +35.1% for SPY (beat the market by 737.3%).
$10,000 invested 1 year ago→ $87,237 today
vs. S&P 500 (SPY) — same period beat market by 737.3%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($26.19)
✓Above 50-day MA ($36.68)
✓RSI(14) neutral zone (30–70) — currently 54.9
✓Positive return (+772.4%)
!Within 10% of period high (−14.8%)
Period Range $37.25
$4.12$43.73
RSI (14) 54.9
0 · OversoldOverbought · 100
Key Metrics
Price$37.25
Period Return+772.4%
Period High$43.73
Period Low$4.12
Drawdown−14.8%
MA-50$36.68
MA-200$26.19
RSI (14)54.9
Avg Volume (30d)2.5M
vs. SPYbeat by 737.3%
Return Rank#21 of 996
Trend Signals
Price is above the 200-day moving average ($26.19)